New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
16:53 EDTACHNAchillion reports Q2 EPS (16c), consensus (18c)
President and CEO Milind Deshpande said, "We remain committed to our goal of initiating a Phase 2 trial by the end of 2014, pending regulatory approval, which will evaluate ACH-3422 in combination with ACH-3102 for patients with chronic HCV for treatment durations of eight weeks or less. We also remain confident that our strong balance sheet will fund our operations into 2016." Cash, cash equivalents, marketable securities, and interest receivable as of June 30 were $132.2M.
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 3, 2015
05:41 EDTACHNAchillion announces Janssen initiated study to evaluate simeprevir and odalasvir
Achillion announced that Alios Biopharma part of the Janssen Pharmaceutical JNJ)) has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 in healthy volunteers. This phase I study is an open-label, two-group study of simeprevir and odalasvir, a HCV NS5A inhibitor, on the pharmacokinetics of AL-335, a nucleotide-based HCV polymerase inhibitor. The primary objective of the study is to investigate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 when administered in combination to healthy volunteers. As previously announced on May 19, 2015, Achillion has granted Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillionís HCV assets which include odalasvir, ACH-3422, and sovaprevir.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use